Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Pipeline
  • Rejuvenate crowdfunds development of gene therapy for aging, chronic diseases
  • Pipeline

Rejuvenate crowdfunds development of gene therapy for aging, chronic diseases

BioSpace

George Church's Rejuvenate Bio is turning to social networks to help fund its work on one-time gene therapies targeting chronic diseases and root causes of aging.

Gene Therapy Platform

Read full story

pharminent April 27, 2026 (Last updated: April 27, 2026)

BioSpace

George Church’s Rejuvenate Bio is turning to social networks to help fund its work on one-time gene therapies targeting chronic diseases and root causes of aging.

Gene Therapy Platform

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: J&J puts blockbuster blood thinner Xarelto on TrumpRx
Next: GSK/Tesaro claim denied in Jemperli lawsuit with AnaptysBio

Related Stories

  • Pipeline

Sanofi drops two more programmes in R&D clear-out

pharminent July 30, 2026
  • Pipeline

Lundbeck preps for key bexicaserin data around year-end

pharminent July 20, 2026
  • Pipeline

AAIC 2026: Tau-targeted Alzheimer’s treatments heat up while amyloid therapies persist

pharminent July 10, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.